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Abstract The aim of this study was to evaluate the clinical
outcome of CyberKnife stereotactic body radiotherapy
(SBRT) for patients with stage I non-small cell lung cancer
(NSCLC). Fifty patients with peripheral stage I NSCLC who
refused surgery or were medically inoperable were treated
with 48–60 Gy (median dose: 57 Gy) in three divided doses.
Histopathology was available in 86 % of patients. Thirty
patients had a T1 tumor, and 20 patients had T2 tumors.
More than 95 % of the target volume was covered by the
72 % isodose surface. Fiducials were implanted in or near
the tumors in all patients to track tumor movement and
breathing patterns. The median follow-up time was
35 months (3–45 months). Based on computed tomography
scans, 40 patients achieved complete remission, six patients
achieved partial remission, two patients exhibited stable
disease, and two patients had progressive disease. The local
control rate (CR ? PR) was 92 %, and the 2-year disease
control rate (CR ? PR ? SD) was 96 %. Overall survival
for the whole group was 86 % at 1 year and 74 % at 2 years.
Grade III toxicity occurred in two patients (4 %) after
marker placement. Treatment-related late grade III toxicity
occurred in five patients (10 %). Toxicities greater than
grade III were not observed. CyberKnife SBRT achieves a
high rate of local control and long-term curative effect with
acceptable toxicity for patients with inoperable stage I
NSCLC. However, long-term follow-up is necessary to
evaluate survival and late toxicity.
Keywords NSCLC  CyberKnife  SBRT  Clinical
outcomes
Introduction
Surgical resection is the primary treatment for early non-
small cell lung cancer (NSCLC). However, radiotherapy is
the only possible method for treating elderly patients with
poor cardiopulmonary function, with poor body condition,
or with surgical reluctance. Considering lung cancer is
easily affected by respiratory motion, the area needs to be
increased to avoid any leakage during tumor irradiation.
However, because of numerous restrictions, the radiation
dose for tumors is maintained at 60–70 Gy, which leads to
a low control rate [1]. Thus, the 2- and 5-year survival rates
of early peripheral stage I NSCLC are always maintained at
about 39 and 13 % [2], respectively, which are far below
the surgical efficacy [3, 4].
As a new means of radiotherapy, CyberKnife stereo-
tactic body radiotherapy (SBRT) avoids the errors caused
by respiratory movement through synchronous respiratory
tracking technology. By implanting gold fiducials in or
around the tumors, tumor movement synchronized with
respiratory motion can be truly tracked, more accurately
giving the tumor higher doses, while reducing the dose to
normal tissues [5–8].
The planning target volume (PTV) and the volume of
normal lung tissues irradiated by high dose are significantly
reduced because of the high degree of conformity of the
tumor target under CyberKnife SBRT. Thus, the incidence
of radiation pneumonitis decreases significantly. The pur-
pose of this study was to report and to analyze the pre-
liminary clinical efficacy of 50 patients with stage I
NSCLC.
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The study was approved by Ethic Committee of Jinling
Hospital. Patients have provided their written informed
consents to receive the CyberKnife SBRT.
Patients
A total of 50 patients with early (T1–T2a, stage I)
peripheral NSCLC were treated at Radiotherapy Center,
Jinling Hospital between March 2009 and September 2010.
Peripheral lung cancer was defined as the distance from
tumor to bronchus, and main bronchus in the CT was at
least 2 cm. All patients were confirmed by two chief tho-
racic surgeons. All patients refused surgery or had no
surgical indications. Up to 42 patients were diagnosed
through histopathology, whereas eight patients were diag-
nosed through typical clinical manifestations and positron
emission tomography/computer tomography (PET/CT)
imaging. The patient details are shown in Table 1.
Fiducial marker placement
All 50 patients were treated using a CyberKnife SBRT
system (Accuray, USA). All patients were treated via res-
piration synchronous tracking (synchrony), and one to
three markers (size of 6.0 mm 9 8.0 mm) were required to
be implanted within or around the tumor using a CT-guided
19-G needle. CT scan was performed to observe whether
the markers were in the proper positions or to detect the
presence of pneumothorax within 2 h after implantation.
A CT scan was performed again at 7–10 days after
implantation. At this time, local hemorrhage and edema
subsided around the markers, whereas the markers were
relatively stable and no longer moved.
Position and target delineation
Patients were in the supine position with the body fixed
with a vacuum pad. Spiral CT (Sensation 16 PET/CT,
Siemens, Germany) scanning was conducted with a slice
thickness of 1 mm. Pulmonary scans covered 15 cm above
and below the lesions. The gross target volume (GTV) and
PTV were determined according to the tumor volume. The
GTV was contoured using lung window settings. We added
a 8-mm margin to the GTV to account for microscopic
tumor extension and residual inaccuracy of synchrony. The
prescription dose was defined as 100 % of the GTV dose.
The total PTV dose was not less than 80 % of the pre-
scription dose.
Treatment mode and methods
Before treatment, a respiratory monitoring device was used
to detect the position of the infrared generator placed on the
chest of the patient to create a dynamic respiratory rhythm.
The X-ray kV digital images were obtained at different time
points during the respiratory cycle to obtain the dynamics
model between the gold seed fiducial (tumor) position and
respiratory rhythm. Then, the respiratory model was used to
guide the accelerator to track the lesions within the lung and










Left upper lobe 7 (14)
Left lower lobe 9 (18)
Right upper lobe 15 (30)
Right middle lobe 6 (12)
Right lower lobe 11 (22)
Other 2 (4)
Clinical stage
Stage IA 30 (60)
Stage IB 20 (40)
Maximal diameter
B2 cm 13 (26)
[2 cm but B3 cm 17 (34)
[3 cm but B5 cm 20 (40)
Histology 42 (84)
Adenocarcinoma 19 (45.2)
Squamous cell carcinoma 17 (40.5)
Large cell carcinoma 4 (9.5)
Undifferentiated carcinoma 2 (4.8)






FEV1 (L) 1.26 (0.75–3.28)
% Predicted FEV1 57 (23–86)
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to administer the dynamic radiation. The prescription dose of
lesions was 48–60 Gy (median dose 57 Gy) in three divided
doses. The lesions were treated once per day (rest on Satur-
days and Sundays), and the total treatment time was
3–5 days (median 4 days). The equivalent biological dose
was 104–150 Gy when the a/b value was equal to 10. About
130 beams were shot out through 2–3 collimators (size
20–60 mm). The median treatment time was 70 min (rang-
ing from 40 to 130 min) at a dose rate of 400 MU/minute.
During the treatment, antiemetic, dehydration, appetite
improvement, and other appropriate symptomatic treatments
were given when complications such as nausea, vomiting,
fatigue, and anorexia occurred.
Follow-up and appraisal
A chest CT scanning was performed during the 1st, 3rd, 6th,
9th, 12th, 15th, 18th, 21st, and 24th month within 2 years after
treatment. The Response Evaluation Criteria in Solid Tumors,
version 1.1 (RECIST1.1) was used to evaluate treatment effi-
cacy [9]. The Radiation Therapy Oncology Group (RTOG)
radiation injury-grading criterion was used to evaluate radia-
tion injury. Follow-up was performed every 3 months for a
total of 3–45 months, with a median follow-up of 35 months,
and the last follow-up time was in February 2013.
Local recurrence was defined as a 20 % increase in CT
tumor dimension compared with the previous CT scan. In
addition, a PET scan was performed to assist in the diag-
nosis. The local control was calculated from the first day of
treatment until local recurrence was diagnosed. Patients
without a local recurrence were censored on the last day of
contact. Overall survival was measured from the start of
CyberKnife treatment until death of any cause. Cause-
specific survival was measured from the start of Cyber-
Knife treatment until death by lung cancer. Patients alive
until the last date of contact were censored.
Statistical process
SPSS 13.0 statistical software was applied for data analysis. The
Kaplan–Meier method was used to analyze local control and
overall survival. The log-rank method was used to test the sig-
nificance compared with the survival curves. The survival time
was from the date when CyberKnife was used in the treatment.
P value\0.05 was considered statistically significant.
Results
Dosimetry index
Among 50 patients, the tumor PTV ranged from 3.4 to
166.3 cm3, with a median value of 27 cm3. The isodose
level of prescription dose in the treatment plan was from 72
to 88 %, with a median of 78 %. The number of radiation
fields ranged from 150 to 200 of the non-coplanar fields.
The treatment plan showed that the mean Conformity
Index (CI) of the pancreatic lesions in all patients was 1.17,
and the mean New Conformity Index (nCI) was 1.28,
which is shown in Table 2. The standard of dose limitation
in critical structures is shown in Table 3. Figure 1 shows
the dosimetry indicators in the treatment plan of a patient
with stage IB disease (the prescription dose of 75 % iso-
dose level was 60 Gy/3 fractions. The PTV was 58.7 cm3,
the CI of lesion was 1.21, nCI was 1.33, and the coverage
rate was 99.73 %).
Situations of treatment-related complications
Gold seed fiducial marker implantation before treatment
All patients were treated with respiration synchronous
tracking technique and were implanted with the markers
within or around the tumor through CT guided before the
treatment. A total of 112 markers were implanted with the
average quantity of 2.24. One marker was implanted when
the tumors were B2 cm and with an irregular shape. If the
tumors were greater than 2 cm and smaller than 3 cm, two
markers were implanted. If the tumor was[3 cm and with
an irregular shape, three markers were implanted. Grade III
complications occurred in three cases of lung puncture.
Among them, two cases developed pneumothorax caused
by punctures and recovered after 5 days of closed thoracic
drainage. One patient with serious hemoptysis recovered
Table 2 Dosimetry index of the 50 patients during CyberKnife
radiosurgery treatment
Item Median (range)
Tumor diameter (cm) 2.7 (1.0–5.0)
Gross tumor volume (cc) 15.6 (1.0–125)
Prescription dose (Gy) 57 (48–60)
Conformity Index (CI) 1.17 (1.07–1.30)
New Conformity Index (nCI) 1.28 (1.14–1.35)
Coverage (%) 96 (85–100)
Planned tumor volume (cc) 27 (3.4–166.3)
Prescription isodose line (%) 78 (72–88)
Conformity Index (CI): The ratio of the tissue volume that received
the prescription isodose or more to the tumor volume receiving the
prescription isodose or more
New Conformity Index (nCI): The data of the CI multiplied by the
ratio of the total tumor volume to the tumor volume receiving the
prescription isodose or more
Coverage: The volume of the tumor that received greater than or
equal to the prescribed dose divided by the total volume of the tumor
times 100
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through interventional treatment and completed the treat-
ment smoothly. Five cases developed grade II complica-
tions with \30 % pneumothorax who recovered within
2 days via suction through a fine-needle puncture. Eight
cases developed grade I complications, consisting mostly
of mild pneumothorax, local pain, and hemorrhage.
Treatment of related complications
During the CyberKnife SBRT, 32 patients developed fati-
gue and anorexia, whereas the others had no significant
symptoms. Four cases had grade II bone marrow depres-
sion, whereas 16 cases had grade I bone marrow
Fig. 1 Dosimetry index of one patient with stage IB NSCLC during
CyberKnife radio surgery treatment. a Multiple pencil beams
delivered by the CyberKnife converging at the tumor target. Isodose
curves (b axial view; c sagittal view; d coronal view) depict the dose
distribution around the tumor volume, represented by the red line.
The white line shows the 70 % isodose line, the peach blossom line is
the 50 % isodose line, and the light blue line is the 20 % isodose line
Table 3 Standard of dose
limitation in critical structures
Dosis constraints for critical
structures were taken three
fractions as a standard
Critical structures Dose constraints
Volume Dose (Gy per fraction)
Esophagus Any point 9
Trachea and main bronchus Any point 10
Spinal cord Any point 6
Plexus brachialis Any point 8
Liver Any point 20
Lung (right and left) \10 %of the total volume 6.67
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depression. All cases returned to normal after granulocyte
colony-stimulating factor (G-CSF) treatment. After the
treatment, five cases developed grade III complications
during follow-up, with two cases of radiation pneumonitis
that needed hormonal and antibiotic treatment. The cases
recovered after 3 weeks. Three cases had pain in the chest
wall that required morphine for relief. Three cases devel-
oped grade II radiation pneumonitis, whereas eight cases
developed grade I limited radiation pneumonitis, all of
which were localized. After symptomatic treatment, the
cases recovered smoothly. The side effects of all the
patients are shown in Table 4.
Short-term efficacy
All patients completed the treatment successfully, and all
of the 50 cases were evaluated after the treatment. The
results show that 40 cases had CR, six cases had PR, two
cases had SD, and two cases had PD. The efficiency
(CR ? PR) rate of tumor was 92 %, and the disease con-
trol rate (CR ? PR ? SD) was 96 % in 2 years. During
the follow-up period, the disease control rate for stage IA
was 95 %, whereas the 2-year disease control rate was
90 %. All local recurrences were seen among patients with
T2 tumors. Figure 2 shows the CT scan from 1 to 9 months
after treatment in a patient with stage IB disease.
Long-term efficacy and survival situation
Among the 50 patients, the median follow-up time was
35 months and the follow-up rate was 100 %. Three cases
developed local recurrence, six cases developed distant
metastasis, and four cases developed both local recurrence
and distant metastasis. Up to 16 patients died during fol-
low-up: Four patients died of metastatic NSCLC (25 %),
and 12 patients died of intercurrent disease (75 %). The
causes of intercurrent death are summarized in Table 5.
The estimated overall survival was 86 % at 1 year and
74 % at 2 years. The 2-year survival rate was 80 % for
stage IA and was 65 % for stage IB (Fig. 3; P = 0.203).
The cause-specific survival rate was 94 % at 1 year and
86 % at 2 years. The 2-year special disease survival rate
was 93.3 % for stage IA and 75 % for stage IB (Fig. 4;
P = 0.074).
Discussion
Radical radiotherapy is the suitable treatment for patients
who refused to have operations or those who suffer from
stage I NSCLC, but have contraindications for surgery
because of objective reasons. Conventional radiotherapy
improves the prognosis and increases the quality of life of
patients. Although conventional radiotherapy improves the
prognosis and quality of life, the dose is difficult to
increase because the lung tumor target has low conformity
during radiotherapy and it is influenced by respiratory
motion. However, the development of CyberKnife provides
a good solution to this problem. In this study, CyberKnife
was used to treat 50 patients with stage I NSCLC, with an
isodose for the tumor target prescription dose reaching 72
to 88 %. This treatment increased the target conformity
and allowed the surrounding normal tissues to receive only
a small dose of radiation. During the 3–45 months after
treatment, few patients developed adverse reactions such as
weakness, nausea, emesis, and bone marrow depression.
These symptoms were relieved after proper treatments. The
local control rate of the pulmonary lesions reached 92 %
through regular follow-up and chest CT rechecking. Most
of the patients achieved complete remission (the remission
rate was 80 %). The quality of life was almost not influ-
enced significantly.
The efficacy of conventional radiotherapy and three-
dimensional conformal radiotherapy in stage I NSCLC is
difficult to improve, which is mainly because real-time
position tracking is impossible during treatment. Cyber-
Knife SBRT with synchrony technology is one of the most
mature real-time tracking technologies for clinical appli-
cations, and the relevant research results show accuracy up
to around 1.5 mm [10]. Therefore, this technology reduces
the uncertainty of tumor location through respiration
adaptive tracking system and decreases the PTV caused by
respiratory movement. This technology reduces the target
volume, increases the effective dose, reduces the toxicity to
normal tissues, and it significantly improves the efficacy
[10–12]. Of the 50 patients in this study, all received
synchronous respiratory tracking technique (synchrony)
using gold seed fiducials implanted into the tumors. During
the completion process of plans, 80 % of average isodose
Table 4 Side effects of 50 patients with NSCLC in CyberKnife
radiosurgery treatment (%)
Classification in WHO and RTOG
0 1 2 3 4
Acute side effects
Leukopenia 35 (70) 12 (24) 3 (6) 0 (0) 0 (0)
Thrombocytopenia 45 (90) 4 (8) 1 (2) 0 (0) 0 (0)
Hemoglobin; 47 (94) 2 (4) 1 (2) 0 (0) 0 (0)
Fatigue 18 (36) 32 (64) 0 (0) 0 (0) 0 (0)
Anorexia 30 (60) 20 (40) 0 (0) 0 (0) 0 (0)
Late side effects
Pain 40 (80) 5 (10) 2 (4) 3 (6) 0 (0)
Radiation pneumonia 37 (74) 8 (16) 3 (6) 2 (4) 0 (0)
Med Oncol (2015) 32:55 Page 5 of 8 55
123
wrapped the target volume, with the CI reaching 1.17 and
the nCI reaching 1.28. By increasing the tumor dose, Cy-
berKnife significantly reduces the dose to normal tissues.
The results show that CyberKnife needed only three times
sessions in treating NSCLC, and the short-term efficacy
was positive, with a total effective rate (CR ? PR) of
92 %. The survival rate was 86 % at 1 year and 74 % at
2 years. The disease-specific survival rate was 94 % at
1 year and 86 % at 2 years. As a new exploration in the
treatment of early-stage NSCLC, CyberKnife is similar to
the surgery in terms of survival rate, and it has an increased
local control rate.
Although the CyberKnife has its high accuracy, the
border was still the problem during CyberKnife SBRT. A
poorly controlled border range PTV could result in slight
tumor metastasis, recurrence, or residues. During the
Fig. 2 a Enhanced CT image of
a patient with stage IB NSCLC
before CyberKnife radiosurgery
treatment. The arrows show the
tumor before Cyberknife
radiosurgery treatment; b The
tumor volume decreased
significantly at almost 1 month
after CybernKnife radiosurgery
tratement; c The tumor volume
decreased much more
significantly at almost 6 months
after Cyberknife radiosurgery
treatment, but with some
inflammation; d The tumor was
destroyed and almost
disappeared at 9 months after
CyberKnife radiosurgery
treatment
Table 5 Characteristics of






Male 78 80 Cerebrovascular infarction
Male 82 70 Cerebrovascular infarction
Male 85 60 Myocardial infarction
Female 79 80 Myocardial infarction
Female 84 70 Myocardial infarction
Male 92 60 Respiratory failure
Female 89 70 Respiratory failure
Male 80 90 Traffic accident
Male 76 80 Sudden death
Female 83 70 Cardiac decompensation after dialysis
Male 65 70 Cardiac decompensation
Male 72 80 General deterioration
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planning of CyberKnife, defining the correct PTV range
correctly is difficult. Timmerman [13] conducted the first
test on increasing the dose of CyberKnife treatment for
stage I NSCLC in 2003. The result showed that if the
border was controlled within 1 cm, a dose of 60 Gy used
three times in 2 weeks was safe. Moreover, Giraud [14]
reported that 96 % of cases were had malignant tumor cells
ranging from 6 to 8 mm beyond the GTV. Based on this
result, Brown [15] extended the primary tumor from 8 to
10 mm and the metastatic tumor from 3 to 5 mm,
achieving good results using CyberKnife SBRT. Thus, in
the present study, we combined the residual inaccuracy of
the synchrony and the micrometastatic characteristics of
the tumor. PTV was defined as the border by extending the
GTV to 8 mm to cover the border, which covers slight
metastasis or unpredictable motion errors. From the results
obtained from the 35 months of observation, the 2-year
local control rate reached 96 %, which also showed that the
boundary should be extended by 8 mm.
The problem of treatment dosage administration of
CyberKnife SBRT has confused many experts. If the dose
is too high, the tumor control rate is high, but the com-
plications also increase. If the dose is too low, the com-
plications are decreased, but the tumor control rate is low.
Timmerman [16] treated 70 patients with stage T1 or T2
(B7 cm) NSCLC with N0 and M0 pathology. The number
of patients was 35 for both T1 and T2, including the
peripheral and the central-type patients. The total dose of
all patients was 60–66 Gy, divided into three sessions. The
treatment was completed within 1–2 weeks. The results
showed that the 2-year local control rate was 95 %, the
median survival rate was 32.6 months, the 2-year overall
survival rate was 54.7 %, and 28 patients died during fol-
low-up. Among those treated for central lung cancer, five
cases died of related cancer, six cases died of related
treatment, and 17 cases died of related complications. For
the patients with peripheral lung cancer, 83 % of patients
did not have serious treatment-related toxicity within
2 years, but only 54 % of the central-type patients did not
have serious toxicity. The results show that the peripheral
lung cancers are well tolerated. Vander Voort vanzyp [17]
treated 70 patients with stage I peripheral NSCLC in 2009,
who were treated at 45 and 60 Gy, the division of which
was completed in three times. Thus, the 2-year local con-
trol rate was 96 % at 60 Gy in 2 years, and the 45 Gy
group was 78 % (P = 0.197). The 1-year overall survival
rate was 83 %, whereas the 2-year overall survival rate was
62 %. The 60 Gy group did not have treatment-related
complications more than grade III. The results from two
authoritative studies showed that treating stage I peripheral
NSCLC with 60 Gy in three divided doses is safe.
Based on these studies, the patients in our group were all
stage I peripheral NSCLC. A dosage from 48 to 60 Gy was
given for patients with poor lung function, but the total
dose of 60 Gy was given for more than 60 % patients. The
2-year local rate was 96 % in three divided doses, similar
to the reported studies [18]. However, the overall survival
rate was 74 % in 2 years, slightly higher than that in the
reported study [19]. Presumably, patient selection may play
a role in the variation of overall survival.
The major symptoms of toxicity of CyberKnife SBRT
include short-term weakness, nausea, and mild hemato-
logic toxicity, which improved through active symptomatic
treatment. The long-term adverse reactions are mainly
Fig. 3 Overall survival of patients. Overall survival of patients with
stage IA (n = 30) and stage IB tumors (n = 20) treated with real-time
tumor tracking using CyberKnife (P = 0.203)
Fig. 4 Cause-specific survival of patients. Cause-specific survival of
patients with stage IA (n = 30) and stage IB tumors (n = 20) treated
with real-time tumor tracking using CyberKnife (P = 0.07)
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local pain and local radiation pneumonia, which improved
and returned to normal through positive symptomatic
treatment. Long-term radiation therapy-related toxicity
greater than grade III was not observed during the 2-year
observation. The toxicity reaction increased with the pro-
longation of follow-up time. However, compared with
other clinical studies [20] with median follow-up time of
12 months, we did not find any apparent increase in tox-
icity. However, further attention to clinical observations
and follow-up is necessary to determine whether the long-
term adverse reactions will occur.
The samples selected in the present study were stage I
peripheral NSCLC, which has its limitations. CyberKnife
SBRT is still a new technology, and clinical experience in
the dosing and frequency of treatment for Asians is limited,
especially in Chinese populations. During the treatment,
we mainly referred to the clinical experience in North
America and Europe, and the treatment modalities and
doses were still in the exploratory stage. Central NSCLC
limited the dose and the implantation of markers because of
the proximity to the trachea and main bronchi. Thus,
selecting treatment cases should be done more carefully.
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